Juan Zhang

Juan Zhang

Auto-generated profile, based on publicly available information

Juan Zhang

Phase I Clinical Trial Ward, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in Breast Cancer
Verified
Journal Article
Open access
PDF file
JZJuan Zhang
Juan Zhang
QTQi Tian
Qi Tian
MZMi Zhang
Mi Zhang
HWHui Wang
Hui Wang
LWLei Wu
Lei Wu
JYJin Yang
Jin Yang
Breast cancer is a commonly diagnosed female cancer in the world. Triple-negative breast cancer (TNBC) is the most dangerous and biologically aggressive subtype in breast cancer which has a high mortality, high rates of relapse and poor prognosis, representing approximately 15–20% of breast cancers. TNBC has unique and special biological molecular characteristics and higher immunogenicity than other breast cancer types. On the basis of molecular features, TNBC is divided into different subtypes and gets various treatments. Especially, immunotherapy becomes a promising and effective treatment to TNBC. However, not all of the TNBC patients are sensitive to immunotherapy, the need of selecting the patients suitable for immunotherapy is imperative. In this review, we discussed recent discoveries about the immune-related factors of TNBC, including tumor-infiltrating lymphocytes (TILs), programmed death-ligand protein-1 (PD-L1), immune gene signatures, some other emerging biomarkers for immunotherapy effectivity and promising biomarkers for immunotherapy resistance. In addition, we summarized the features of these biomarkers contributing to predict the prognosis and effect of immunotherapy. We hope we can provide some helps or evidences to clinical immunotherapy and combined treatment for TNBC patients.

12 November 2024 in The FASEB Journal
Verified
Journal Article
Open access
XGXiaoqian Gao
Xiaoqian Gao
JLJuan Li
Juan Li
XFXuefei Feng
Xuefei Feng
YXYuchen Xie
Yuchen Xie
JZJuan Zhang
Juan Zhang
PLpeijun liu
peijun liu
The multistep dynamic process of metastasis is the primary cause of breast cancer deaths. C‐terminal Eps15‐homology domain‐containing protein 1 (EHD1), a translocator associated with endocytic recycling, has been implicated in various oncogenic processes. However, the precise molecular mechanisms of EHD1‐induced breast cancer metastases remain largely unexplored. Here we found that the upregulation of EHD1 in breast cancer was positively associated with distant lymph node metastasis in patients. Meanwhile, EHD1 promoted epithelial‐mesenchymal transition (EMT), invasion, and metastasis of breast cancer cells in both two‐dimensional (2D) and three‐dimensional (3D) culture models in vitro, as well as in vivo. Remarkably, EHD1 can activate the AKT–mTOR pathway to upregulate the protein expression of hypoxia‐inducible factor 2α (HIF2α) under normoxic conditions and subsequently enhance the invasive and metastatic breast cancer. Our findings indicated EHD1 as a new regulator of HIF2α and a potential therapeutic target for inhibiting breast cancer metastasis.

19 December 2025 in Science Advances
Verified
Journal Article
Open access
HGHuan Gao
Huan Gao
BCBo Cheng
Bo Cheng
GJGuorui Jin
Guorui Jin
YHYulong Han
Yulong Han
QTQi Tian
Qi Tian
FXFeng Xu
Feng Xu
The extracellular matrix (ECM) acts as a primary physical barrier to cancer metastasis. While individual cancer cells can remodel ECM to create microchannel-like paths of least resistance, this cell-centric view overlooks the coordinated dynamics of multicellular communication. Here, we reveal that cancer cells collaboratively reprogram ECM to construct interconnected microchannel networks functioning as “superhighways” for barrier-free metastasis. Combining live-cell imaging, atomic force microscopy, and optical tweezers, we decode that the indispensable step in microchannel network construction is organized cross-convergence of adjacent channels. The convergence is precisely directed by mechanical bridges composed of aligned collagen bundles between adjacent channels, which transmit orientation cues to induce multicellular force coordination. Integrating single-cell sequencing and off-lattice agent-based model, we identify mechanically responsive leader cells enriched for integrin-RhoA/YAP signaling and matrix metalloproteinase 14, which sense bridge cues and initiate cross-convergence. Collectively, our findings unveil a self-organized metastatic network and its mechanobiological mechanisms, offering a previously unidentified framework and potential therapeutic insights for cancer metastasis.

3 January 2026 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
MZMi Zhang
Mi Zhang
JZJuan Zhang
Juan Zhang
YZYan Zhou
Yan Zhou
AZAndi Zhao
Andi Zhao
HWHui Wang
Hui Wang
JYJin Yang
Jin Yang
Tumor metastasis is a major factor of high recurrence and mortality in clear cell renal cell carcinoma (ccRCC), but its underlying mechanism remains elusiv

24 September 2026 in Cell Reports
Verified
Journal Article
Open access
JZJuan Zhang
Juan Zhang
YHYulong Han
Yulong Han
HGHuan Gao
Huan Gao
MZMi Zhang
Mi Zhang
XGXiaoqian Gao
Xiaoqian Gao
FXFeng Xu
Feng Xu
Breast cancer progression and therapy resistance remain major clinical obstacles. Although extensive research has focused on biochemical signals within the tumor microenvironment (TME), the contribution of physical cues, particularly the viscosity of interstitial extracellular fluid (ECF), has been largely overlooked. Here, we provide mechanobiological evidence that elevated ECF viscosity in the TME drives immunosuppressive M2-like macrophage polarization, which in turn promotes breast cancer growth and metastasis. Notably, increased ECF viscosity contributes to resistance to anti-PD-1 immunotherapy. We demonstrate that high ECF viscosity skews macrophages toward a pro-tumoral phenotype through integrin-mediated mechanotransduction, which activates focal adhesion kinase (FAK) and downstream signal transducer and activator of transcription 3 (STAT3), along with extensive cytoskeletal remodeling and nuclear deformation. Collectively, these findings establish ECF viscosity as a critical physical and immunological regulator and suggest it as a potential biophysical therapeutic target in breast cancer.